

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a	valid OMB control number.
Application Number	09/900,567
Filing Date	July 6, 2001
First Named Inventor	Carlos Plata-Salaman
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1453

U.S. PATENT DOCUMENTS									
U.S. Patent Document							T		
Examiner Initials	Cite No.1	Number	Kind C		Name of Patentee or Appli of Cited Document	cant	Date of Publication of Cited Documen mm-dd-yyyy		sages
ws_	DA	4,513,006	$\searrow \bot$		Maryanoff et al		04/23/4985	BEFIVE	<u>-</u> n
WH	DB	242,942	_) /		-Goetanzo et al		09/07/1998	7.0	<u> </u>
ent	M.	5,387,700	/ /		Maryanoff et al	_/_	02/07/1995	JUN \$ 4 200)3
cut	DD	6,071,537			R. Shank		06/06/2000	J CENTER 1000	18845
W.	DE	6,191,163	(<u>_</u>		S. Cottrell		02/20/2001	CENTER 1800	/2900
		_			· · · · · · · · · · · · · · · · · · ·				
<u> </u>									
			<u> </u>						
						-			
							· ·		
				FORE	IGN PATENT DOCUMENTS				
		Foreign Patent Document					ate of Publication f Cited Document	Pages, Columns, Lines, where relevant passages or relevant	
Examiner Initials	Cite No. ¹	Office ³ Numl	oer⁴ KindC	code ⁵	Applicant of Cited Documen	ıt	mm-dd-yyyy	figures appear	Τ ⁶
200	QF	VO 00/6	1139 A	(7)	Ortho-McNeil Pharmaceutical II)c. 10)/19/2006	7	
ext=	攻	vo 00/6	1140	4	Ortho-McNeil Pharmaceutical, Ir		0/ 9/2000		
KOF	DI-	WO 69/4		12	Ortho-McNeil Fharmageutical, Ir	-/- 	0/1999	//_	
KAF	Dt	WO 00/5		2	University of Gincinnati	1	3/31/2000		ļ ·
MA	DJ_	00/7	5493 / A	\1	- Najarian	12	2/21/2000		
1				1					1 1

Examiner Signature	RR Ovala	Date Considered	7-8-03			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance						

and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a collection of information unless it displays a	I Valid CIVID CONTROL HUMBER.
Application Number	09/900,567
Filing Date	July 6, 2001
First Named Inventor	Carlos Plata-Salaman
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1453

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
WE	DK	CROOKE et al. ABSTRACT, Topiramate Improves Glycemic Control Independent of Weight Loss in ob/ob Mice, diabetes, A Journal of the American Diabetes Association, Abstract Book 61st Scientific Sessions Friday, June 22 - Tuesday June 26, 2001, 2158-PO, A513	_
KICF	DL	DEMAREST ET AL ABSTRACT Topirmate Improves Glucose Tolerance and May Improve Insulin Sensitivity in Animal Models of Type 2 Diabetes Mellitus, diabetes, A Journal of the American Diabetes Association, Abstract Book 61 st Scientific Sessions Friday, June 22 - Tuesday June 26, 2001, 1254-P, A302	
VCF	DM	OSBORNE ET AL ABSTRACT Topiramate Improves Glycemic Control and Triglycerides in Animal Models 1 page The Posters were presented at the Amierican Diabetes Association Conference held June 22-26 in Philadelphia, diabetes, A Journal of the American Diabetes Association, Abstract Book 61 st Scientific Sessions Friday, June 22 - Tuesday June 26, 2001, 1255-P, A302	
	 		
	-		
	 	IIIN 0 4 2003	-
	1	JUN 2 4 2003	
		TECH CENTER 1600/	900
- "			
	 		
	-		
	 		t

Examiner	2n 1	Date	7 6 - 5	
Signature	KK Oonse	Considered	7-0-0-5	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.